Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Says Big Deals Create Value & 10 Other Notable Q3 Moments

Executive Summary

Pfizer's third quarter earnings call covered a lot of ground, from pipeline updates, management's latest thinking on M&A, and strategic options for consumer healthcare, to industry trends like Amazon entering the drug distribution arena.

You may also be interested in...

Futurology: Are Mega Mergers A Thing Of The Past?

Bolt-ons or big-ticket buys? As another year passes without a big pharma mega merger despite industry giants sitting on large cash piles, we consider whether 2018 will bring major upheaval in the industry landscape, and where M&A will be most likely to take place.

PD-1 Earnings Roundup: Buckle Up For A Bumpy Ride

Results from a number of Phase III studies in non-small cell lung cancer for major immuno-oncology players are coming soon, with potential to change the market dynamics.

Novartis's Kisqali Gains Traction In Pre-Menopausal Patients

Top-line Phase III data from the MONALEESA-7 study could lead to an extension of Kisqali's indications into pre-menopausal women with a certain type of breast cancer, helping it gain traction in the highly competitive CDK4/6 inhibitor market.

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts